Andrew Hughes
Director/Board Member chez CellCentric Ltd.
Profil
Andrew Hughes is currently a Non-Executive Director at CellCentric Ltd.
and a Strategy Director at Manchester Cancer Research Centre.
Previously, he worked as the Chairman of Translational Medicine at The University of Manchester, an Independent Director at PCI Biotech Holding ASA, and the Worldwide Clinical Head of Early Phase Oncology at AstraZeneca AS.
Postes actifs de Andrew Hughes
| Sociétés | Poste | Début |
|---|---|---|
| Manchester Cancer Research Centre | Corporate Officer/Principal | - |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 06/04/2022 |
Anciens postes connus de Andrew Hughes
| Sociétés | Poste | Fin |
|---|---|---|
| PCI BIOTECH HOLDING ASA | Director/Board Member | 25/05/2023 |
| The University of Manchester | Corporate Officer/Principal | - |
| AstraZeneca AS | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PCI BIOTECH HOLDING ASA | Health Technology |
| Entreprise privées | 3 |
|---|---|
| AstraZeneca AS | |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Manchester Cancer Research Centre |
